Equibles does not estimate personal net worth.
Get an email with a short summary when Strata Critical Medical, Inc. publishes a filing, an earnings call transcript or a press release.
Get SRTA alertsWilliam Heyburn is recorded as Board Member at Strata Critical Medical, Inc. (SRTA) since January 1, 2025 and CEO and CFO at Strata Critical Medical, Inc. (SRTA). The newest filing on record that lists William Heyburn as CEO and Board Member at Strata Critical Medical, Inc. (SRTA) is dated April 14, 2026. The newest filing on record that lists William Heyburn as CFO at Strata Critical Medical, Inc. (SRTA) is dated March 22, 2024. Strata Critical Medical, Inc. reported in an 8-K filed August 29, 2025 that William Heyburn was appointed Class II director, effective August 29, 2025. Strata Critical Medical, Inc. reported in an 8-K filed August 29, 2025 that William Heyburn was appointed co-Chief Executive Officer, effective August 29, 2025. The proxy statement of Strata Critical Medical, Inc. reports total compensation of $5,326,170 for William Heyburn in fiscal 2025, including a base salary of $516,667. Disclosed compensation is on record for 2 fiscal years. William Heyburn has spoken on 3 earnings calls across 1 company, most recently for Strata Critical Medical, Inc. on November 10, 2025. Strata Critical Medical, Inc. is classified in the Medical Care Facilities industry within the Healthcare sector. Other leadership on record at Strata Critical Medical, Inc. includes Melissa M. Tomkiel (CEO and General Counsel), Melissa Tomkiel (CEO and Board Member), Robert Wiesenthal (CEO and Chairman) and 7 others.
“Mr. Heyburn to the Board as a Class II director to serve until the Company's 2026 annual stockholders meeting.”
“effective as of the Closing, Melissa Tomkiel, who previously served as the Company's President and General Counsel, and William Heyburn, who previously served as the Company's Chief Financial Officer and Head of Corporate Development, assumed the roles of co-Chief Executive Officers of the Company.”
“It's been a very exciting few months as we closed two transformational transactions during the quarter, both the divestiture of our passenger business and the acquisition of Keystone Perfusion, setting us up incredibly well for long-term growth and value creation.”
“I'm excited for the opportunity to lead Strata alongside Melissa Tomkiel and this exciting next phase of growth for the company.”
“I'll now walk through the financial highlights from the quarter, starting with Passenger. Excluding Canada, which we exited in August 2024, short distance revenue increased 28.1% year-over-year, driven primarily by growth in Europe.”
2025-01-01–present
Last confirmed April 14, 2026
Start not stated–present
Last confirmed April 14, 2026
Start not stated–present
Last confirmed March 22, 2024
Medical Care Facilities · Healthcare
CEO, CFO, Board Member
2025-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Strata Critical Medical, Inc. (SRTA) | Co-Chief Executive Officer and Chief Financial Officer | $516,667 | $5,326,170 |
| 2024 | Strata Critical Medical, Inc. (SRTA) | Co-Chief Executive Officer and Chief Financial Officer | $500,000 | $5,402,874 |
